### **Haematological cancer data and sample submission update April 2018**

Following feedback from NHS GMCs on difficulties submitting data for haemaotological cancers, Genomics England updated their systems on 19 April, 2018.  NHS GMCs now have the facility to extend their haematological cancers recruitment and sample collection.  This summary lists the newly added options to facilitate sample submission and some key tips on sample submission.  Full details are held in the cancer data model appendices and release note circulated to NHS GMCs on 20 April, 2018.  The new cancer data model appendices can be found at this location on the [GMC Network](https://www.networks.nhs.uk/nhs-networks/gmc-network/documents/cancer-sample-tracking-model-3-2.3).

**Additional Haematological cancer subtypes (see Appendix A):**

|  |  |
| --- | --- |
| **Description** | **Preferred Code** |
| Myleoproliferative neoplasms | Myleoproliferative\_neoplasms |
| Acute leukaemia other | acute\_leukaemia\_other |

**Clinic sample types for haematological oncology germline and tumour samples (see Appendix D):**

(New sample types are in green, existing sample types in black)

|  |  |  |  |
| --- | --- | --- | --- |
| **Description** | **Preferred Code** | **Other possible codes** | **Use guidance** |
| **Germline** |   |   |   |
| DNA Saliva (CONSTITUTIONAL DNA) | "dna\_saliva" | "DNA Saliva", "Saliva" |   |
| DNA FF Germline (CONSTITUTIONAL DNA) | "dna\_ff\_germline" | "DNA FF Germline" | e.g. skin biopsies |
| DNA Other Germline (CONSTITUTIONAL DNA) | "dna\_other\_germline" | "DNA Other Germline" | Use only if instructed by Genomics England |
| **Tumour samples** |   |   |   |
| DNA Fluid Tumour (TUMOUR DNA) | "dna\_fluid\_tumour" | "DNA Fluid Tumour" | For use with cytology fluids, e.g. pleural aspirate or ascites as the origin of the sample e.g. for lymphoma |
| DNA Other Tumour (TUMOUR DNA) | "dna\_other\_tumour"  | "DNA Other Tumour" | Use only if instructed by Genomics England |
| DNA Blood from blood in Haematological malignancy Tumour (TUMOUR DNA) | "dna\_blood\_tumour" | "DNA Blood Tumour" |   |
| DNA Bone Marrow Aspirate Tumour Sorted Cells (TUMOUR DNA) (Haem Onc samples) | "dna\_bone\_marrow\_aspirate\_tumour\_sorted\_cells" | "DNA CD138" |   |
| DNA Bone Marrow Aspirate Tumour Cells (TUMOUR DNA) (Haem Onc samples) | "dna\_bone\_marrow\_aspirate\_tumour\_cells" | "DNA Bone Marrow" |   |

**Tumour sample submission tips:**

* Fluid tumour samples *do not require* a tissue type (see Appendix D for the required fields in the sample metadata CSV submission).
* Tumour content assessment *is required* for fluid tumour samples, please give a clinical assessment of the tumour content (see Appendix C for the required fields in the sample test result CSV submission).  Current guidance for completion of tumour content is as follows:
	+ *tumour\_content: Proportion of the total number of nuclei in the submitted sample that are neoplastic nuclei (Low, Medium, High) – Low <40%; Medium 40-60%; High>60%.*
	+ It is recognised that for the tumour subtypes of Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MDS), Chronic Myeloid Leukaemia (CML) and Unclassified haematological malignancies it is often not possible to determine the neoplastic cell morphologically. In these cases, providing the non-lymphoid component of nucleated cells exceeds 60%, the 'high' category should be chosen.
	+ For acute leukaemias the tumour content should be taken to be the blast percentage. It is acknowledged that this will be <40% on occasion meaning the tumour content maps to low. In these instances the sample will still be eligible (please see Sample Handling Guidance v4 section 3.441 for Haematological Cancer sample specifications on the [GMC Network](https://www.networks.nhs.uk/nhs-networks/gmc-network/documents/sample-handling-guidance-v4.0)).
* The germline ‘other’ and tumour ‘other’ samples are for new sample type submissions that Genomics England and NHS England want to track through the pipeline and should only be used in consultation with Genomics England.